• Daptomycin packaged and labeled.

click on thumbnail to zoom
SKU: D024

Size  
Quantity:
  Click 'Bulk Order' for 10 or more
Price: make selection(s)
Description

Daptomycin is a unique lipopeptide antibiotic derived from Streptomyces roseosporus that is effective against Gram-positive bacteria.  This holoenzyme is composed of three subunits, encoded by the dptA, dptBC, and dptD genes, each responsible for incorporating particular amino acids into the peptide.  The cloned dpt gene cluster allows study of Daptomycin biosynthesis and discovery of novel lipopetides through pathway engineering.  Daptomycin is soluble in water (100 mg/mL), DMSO (100 mM), methanol (5 mg/mL), and ethanol (50 mM).

    CAS Number

    103060-53-3

    Molecular Formula

    C72H101N17O26

    Molecular Weight

    1620.67

    Mechanism of Action

    Daptomycin peptides interact with anionic phospholipids in the membrane of Gram-positive bacteria. Peptides integrate into the membrane by a calcium-mediated process and interact with membrane phospholipid head groups and acyl chains. Finally, a pore or channel is formed which can kill the cell by membrane disruption/depolarization or cellular uptake of daptomycin leading to disruption of intracellular processes such as synthesis of DNA, RNA, and protein which results in bacterial cell death.

    Storage Conditions

    -20°C

    Tariff Code

    2941.90.3000

    Spectrum

    Daptomycin targets only Gram-positive organisms including GRE (glycopeptide-resistant Enterococci) and MRSA (methicillin-resistant Staphylococcus aureus)

    • Vancomycin resistant Enterococcus faecalis≤0.015 μg/mL - 4 μg/mL
    • Methicillin resistant Staphylcoccus aureus - 0.25 μg/mL - 2 μg/mL

    For a complete list of daptomycin MIC values, click here.

Applications

    Microbiology Applications

    Daptomycin has been used to study the impact of Staphylococcal accessory regulator (sarA) on Daptomycin susceptibility of Staphylococcus aureus. The mutation of sarA did not affect the Daptomycin MIC but resulted in increased susceptibility in vivo in the context of an established biofilm (Weiss et al, 2009)

Specifications

    Form

    Powder

    Appearance

    Pale Yellow to Light Brown Powder

    Source

    Streptomyces roseosporus

    Water Content (Karl Fischer)

    ≤5.0%

    Sulfated Ash

    ≤3.0%

    Heavy Metals

    ≤20ppm

References

    References

    Baltz RH, Miao V and Wrigley SK (2005) Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat. Prod. Rep. 22(6):717-741 PMID 16311632

    Miao V et al (2006) Genetic engineering in Streptomyces roseosporus to produce hybrid lipopeptide antibiotics. Chem. Biol. 13(3):269-76 PMID 16638532

    Silverman JA, Perlmutter NG, and Shapiro HM (2003) Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47(8):2538-44 PMID 12878516

    Straus, SK and Hancock REW (2006) Mode of action of the new antibiotic for Gram-positive pathogens Daptomycin: Comparison with cationic antimicrobial peptides and lipopeptides. Biomem. 1758(9):1215-1223

    Weiss EC et al (2009) Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo. Antimicrobial. Agents. Chemother. 53(10):4096-4102 PMID 19651914

Other Items In This Category